Citations to this article
Karin Staflin, … , Rodney Prell, Teemu T. Junttila
Published April 9, 2020
Citation Information: JCI Insight. 2020;5(7):e133757. https://doi.org/10.1172/jci.insight.133757.
Citation Information: JCI Insight. 2020;5(7):e133757. https://doi.org/10.1172/jci.insight.133757.
Target arm affinities determine preclinical efficacy and safety of anti-HER2/CD3 bispecific antibody
Abstract
Systemic cytokine release and on-target/off-tumor toxicity to normal tissues are the main adverse effects limiting the clinical utility of T cell–redirecting therapies. This study was designed to determine how binding affinity for CD3 and tumor target HER2 impact the efficacy and nonclinical safety of anti-HER2/CD3 T cell–dependent antibodies (TDBs). Affinity was found to be a major determinant for the overall tolerability. Higher affinity for CD3 associated with rapidly elevated peripheral cytokine concentrations, weight loss in mice, and poor tolerability in cynomolgus monkeys. A TDB with lower CD3 affinity was better tolerated in cynomolgus monkeys compared with a higher CD3–affinity TDB. In contrast to tolerability, T cell binding affinity had only limited impact on in vitro and in vivo antitumor activity. High affinity for HER2 was critical for the tumor-killing activity of anti-HER2/CD3 TDBs, but higher HER2 affinity also associated with a more severe toxicity profile, including cytokine release and damage to HER2-expressing tissues. The tolerability of the anti-HER2/CD3 was improved by implementing a dose-fractionation strategy. Fine-tuning the affinities for both the tumor target and CD3 is likely a valuable strategy for achieving maximal therapeutic index of CD3 bispecific antibodies.
Authors
Karin Staflin, Christina L. Zuch de Zafra, Leah K. Schutt, Vanessa Clark, Fiona Zhong, Maria Hristopoulos, Robyn Clark, Ji Li, Mary Mathieu, Xiaocheng Chen, Jennifer Johnston, Justin Low, Ryan Ybarra, Dionysos Slaga, Jihong Yang, Meric Ovacik, Noël O. Dybdal, Klara Totpal, Melissa R. Junttila, Diego Ellerman, Genee Lee, Mark S. Dennis, Rodney Prell, Teemu T. Junttila
Citation information
Citations to this article (58)
| Title and authors | Publication | Year |
|---|---|---|
|
Mechanistic PKPD modeling to describe cytokine release associated with CD3 T-cell engager therapies
Lefèvre A, Parra-Guillen ZP, Trocóniz IF, Boetsch C, Frances N |
Frontiers in Immunology | 2025 |
|
Bispecific antibodies as powerful immunotherapeutic agents for urological cancers: Recent innovations based on preclinical and clinical evidence
Hushmandi K, Einollahi B, Lee EH, Sakaizawa R, Glaviano A, Reiter RJ, Saadat SH, Farani MR, Huh YS, Aref AR, Salimimoghadam S, Kumar AP |
International Journal of Biological Sciences | 2025 |
|
Quantifying antibody binding: techniques and therapeutic implications
Lodge J, Kajtar L, Duxbury R, Hall D, Burley GA, Cordy J, Yates JW, Rattray Z |
mAbs | 2025 |
|
JNJ-78306358, a first-in-class bispecific T cell engaging antibody targeting CD3 and HLA-G
Obermajer N, Zwolak A, van de Ven K, Versmissen S, Menard K, Rogers K, Petley T, Weinstock D, Aligo J, Patel J, Tian K, Angelillo L, Yi F, Jarantow S, Schutsky K, Hamuro Y, Arias DA, Buyens K, Sheena Yao TW, Torti V, Brajic A, Geist B, van Heerden M, Chu G, Verbist B, Ongenaert M, Häsler J, Packman K, Shenton J, Lenox L, Clawson J, Brown RJ, Lauring J, Greger JG, Brehmer D, Singh S, Lorenzi MV, Laquerre S |
iScience | 2025 |
|
The present and future of bispecific antibodies for cancer therapy.
Klein C, Brinkmann U, Reichert JM, Kontermann RE |
Nature reviews. Drug discovery | 2024 |
|
Using protein geometry to optimize cytotoxicity and the cytokine window of a ROR1 specific T cell engager.
Zhou X, Geyer FK, Happel D, Takimoto J, Kolmar H, Rabinovich B |
Frontiers in immunology | 2024 |
|
Stepping forward: T-cell redirecting bispecific antibodies in cancer therapy.
Qin X, Ning W, Liu H, Liu X, Luo W, Xia N |
Acta pharmaceutica Sinica. B | 2024 |
|
CD3-engaging bispecific antibodies trigger a paracrine regulated wave of T-cell recruitment for effective tumor killing.
Liao CY, Engelberts P, Ioan-Facsinay A, Klip JE, Schmidt T, Ruijtenbeek R, Danen EHJ |
Communications biology | 2024 |
|
Design of Crosslinking Antibodies For T-Cell Activation: Experimental and Computational Analysis of PD-1/CD137 Bispecific Agents.
Kopp A, Guan J, Johnston C, Vance S, Legg J, Galson-Holt L, Thurber GM |
The AAPS journal | 2024 |
|
IL-2-armored peptide-major histocompatibility class I bispecific antibodies redirect antiviral effector memory CD8+ T cells to induce potent anti-cancer cytotoxic activity with limited cytokine release
Schardt JS, Walseng E, Le K, Yang C, Shah P, Fu Y, Alam K, Kelton CR, Gu Y, Huang F, Lin J, Liu W, Dippel A, Zhang H, Mulgrew K, Pryts S, Chennupati V, Chen HC, Denham J, Chen X, Pradhan P, Wu Y, Hardman C, Zhao C, Kierny M, Song Y, Dovedi SJ, Cemerski S, Mazor Y |
mAbs | 2024 |
|
Targeting CD276 for T cell-based immunotherapy of breast cancer.
Hagelstein I, Wessling L, Rochwarger A, Zekri L, Klimovich B, Tegeler CM, Jung G, Schürch CM, Salih HR, Lutz MS |
Journal of translational medicine | 2024 |
|
Antibody avidity meets multiple myeloma.
Ruuls SR, Parren PWHI |
Nature cancer | 2024 |
|
Novel tri-specific T-cell engager targeting IL-13Rα2 and EGFRvIII provides long-term survival in heterogeneous GBM challenge and promotes antitumor cytotoxicity with patient immune cells
Park DH, Bhojnagarwala PS, Liaw K, Bordoloi D, Tursi NJ, Zhao S, Binder ZA, O\u2019Rourke D, Weiner DB |
Journal for Immunotherapy of Cancer | 2024 |
|
T cell‐dependent bispecific antibodies alter organ‐specific endothelial cell–T cell interaction
Himmels P, Nguyen TT, Mitzner MC, Arrazate A, Yeung S, Burton J, Clark R, Totpal K, Jesudason R, Yang A, Solon M, Eastham J, Modrusan Z, Webster JD, Lo AA, Piskol R, Ye W |
EMBO reports | 2023 |
|
eIg-based bispecific T-cell engagers targeting EGFR: Format matters
Kühl L, Schäfer AK, Kraft S, Aschmoneit N, Kontermann RE, Seifert O |
mAbs | 2023 |
|
Structure-based engineering of a novel CD3ε-targeting antibody for reduced polyreactivity
Liu CY, Ahonen CL, Brown ME, Zhou L, Welin M, Krauland EM, Pejchal R, Widboom PF, Battles MB |
mAbs | 2023 |
|
An optimized IgG-based B7-H3xCD3 bispecific antibody for treatment of gastrointestinal cancers
Zekri L, Lutz M, Prakash N, Manz T, Klimovich B, Mueller S, Hoerner S, Hagelstein I, Engel M, Chashchina A, Pfluegler M, Heitmann JS, Jung G, Salih HR |
Molecular Therapy | 2023 |
|
A spike-targeting bispecific T cell engager strategy provides dual layer protection against SARS-CoV-2 infection in vivo
Li F, Xu W, Zhang X, Wang W, Su S, Han P, Wang H, Xu Y, Li M, Fan L, Zhang H, Dai Q, Lin H, Qi X, Liang J, Wang X, Jiang S, Xie Y, Lu L, Yang X |
Communications biology | 2023 |
|
Unleashing NK- and CD8 T cells by combining monalizumab and trastuzumab for metastatic HER2-positive breast cancer: Results of the MIMOSA trial
Geurts VC, Voorwerk L, Balduzzi S, Salgado R, Van de Vijver K, van Dongen MG, Kemper I, Mandjes IA, Heuver M, Sparreboom W, Haanen JB, Sonke GS, Horlings HM, Kok M |
2023 | |
|
Hydrophobic interactions dominate the recognition of a KRAS G12V neoantigen.
Wright KM, DiNapoli SR, Miller MS, Aitana Azurmendi P, Zhao X, Yu Z, Chakrabarti M, Shi W, Douglass J, Hwang MS, Hsiue EH, Mog BJ, Pearlman AH, Paul S, Konig MF, Pardoll DM, Bettegowda C, Papadopoulos N, Kinzler KW, Vogelstein B, Zhou S, Gabelli SB |
Nature Communications | 2023 |
|
Bispecific antibodies in cancer therapy: Target selection and regulatory requirements
Sun Y, Yu X, Wang X, Yuan K, Wang G, Hu L, Zhang G, Pei W, Wang L, Sun C, Yang P |
Acta pharmaceutica Sinica. B | 2023 |
|
Construction of IgG–Fab2 bispecific antibody via intein-mediated protein trans-splicing reaction
Yamada R, Nakahara I, Kumagai I, Asano R, Nakanishi T, Makabe K |
Scientific Reports | 2023 |
|
Bispecific T-Cell Engagers and Chimeric Antigen Receptor T-Cell Therapies in Glioblastoma: An Update
Alsajjan R, Mason WP |
Current Oncology | 2023 |
|
Asymmetric anti-CLL-1×CD3 bispecific antibody, ABL602 2+1, with attenuated CD3 affinity endows potent antitumor activity but limited cytokine release
Lee E, Lee S, Park S, Son YG, Yoo J, Koh Y, Shin DY, Lim Y, Won J |
Journal for ImmunoTherapy of Cancer | 2023 |
|
Longitudinal evaluation of the biodistribution and cellular internalization of the bispecific CD3xTRP1 antibody in syngeneic mouse tumor models
Sandker GG, Middelburg J, Wilbrink E, Molkenboer-Kuenen J, Aarntzen E, van Hall T, Heskamp S |
Journal for ImmunoTherapy of Cancer | 2023 |
|
Novel NKG2D-directed bispecific antibodies enhance antibody-mediated killing of malignant B cells by NK cells and T cells
Lutz S, Klausz K, Albici AM, Ebinger L, Sellmer L, Teipel H, Frenzel A, Langner A, Winterberg D, Krohn S, Hust M, Schirrmann T, Dübel S, Scherließ R, Humpe A, Gramatzki M, Kellner C, Peipp M |
Frontiers in immunology | 2023 |
|
Mechanistically modeling peripheral cytokine dynamics following bispecific dosing in solid tumors
Weddell J |
The Journal of Pathology | 2023 |
|
Revolutionizing cancer immunotherapy: unleashing the potential of bispecific antibodies for targeted treatment
Guo X, Wu Y, Xue Y, Xie N, Shen G |
Frontiers in immunology | 2023 |
|
Tuning the potency and selectivity of ImmTAC molecules by affinity modulation
Robertson IB, Mulvaney R, Dieckmann N, Vantellini A, Canestraro M, Amicarella F, O\u2019Dwyer R, Cole DK, Harper S, Dushek O, Kirk P |
Clinical & Experimental Immunology | 2023 |
|
Superantigen-fused T cell engagers for tumor antigen-mediated robust T cell activation and tumor cell killing
Zhao WB, Shen Y, Cai GX, Li YM, Liu WH, Wu JC, Xu YC, Chen SQ, Zhou Z |
Molecular Therapy | 2023 |
|
Physiological Considerations for Modeling in vivo Antibody-Target Interactions
T Dunlap, Y Cao |
Frontiers in pharmacology | 2022 |
|
Novel strategies for the mitigation of cytokine release syndrome induced by T cell engaging therapies with a focus on the use of kinase inhibitors
Leclercq G, Steinhoff N, Haegel H, De Marco D, Bacac M, Klein C |
OncoImmunology | 2022 |
|
Insights into intercellular receptor-ligand binding kinetics in cell communication
An C, Wang X, Song F, Hu J, Li L |
Frontiers in Bioengineering and Biotechnology | 2022 |
|
Nonclinical Pharmacokinetics and Pharmacodynamics Characterization of Anti-CD79b/CD3 T Cell-Dependent Bispecific Antibody Using a Surrogate Molecule: A Potential Therapeutic Agent for B Cell Malignancies.
Yadav R, Sukumaran S, Zabka TS, Li J, Oldendorp A, Morrow G, Reyes A, Cheu M, Li J, Wallin JJ, Tsai S, Sun L, Wang P, Ellerman D, Spiess C, Polson A, Stefanich EG, Kamath AV, Ovacik MA |
Pharmaceutics | 2022 |
|
Characterization of anti-CD79b/CD3 bispecific antibody, a potential therapy for B cell malignancies.
Wang J, Li C, He K, Kuang Z, Lu J, Yao Y, He F, Li N, Li L, Fu F, Wu Z, Zhou S, Kang D, Qiu X, Wu M, Liu Y, Cao X, Xu M, Chen B, Wu W, Guo F |
Cancer Immunology, Immunotherapy | 2022 |
|
Antibody variable region engineering for improving cancer immunotherapy.
Lou H, Cao X |
2022 | |
|
In vivo DNA-launched bispecific T cell engager targeting IL-13Rα2 controls tumor growth in an animal model of glioblastoma multiforme.
Bhojnagarwala PS, O'Connell RP, Park D, Liaw K, Ali AR, Bordoloi D, Cassel J, Tursi NJ, Gary E, Weiner DB |
2022 | |
|
Immobilization-Free Binding and Affinity Characterization of Higher Order Bispecific Antibody Complexes Using Size-Based Microfluidics
Madsen AV, Mejias-Gomez O, Pedersen LE, Skovgaard K, Kristensen P, Goletz S |
Analytical Chemistry | 2022 |
|
Heart failure and cancer: From active exposure to passive adaption.
Du Y, Wu T |
Frontiers in Cardiovascular Medicine | 2022 |
|
Current landscape and future directions of bispecific antibodies in cancer immunotherapy
Wei J, Yang Y, Wang G, Liu M |
Frontiers in immunology | 2022 |
|
TriTECM: A tetrafunctional T-cell engaging antibody with built-in risk mitigation of cytokine release syndrome
Carrara SC, Harwardt J, Grzeschik J, Hock B, Kolmar H |
Frontiers in immunology | 2022 |
|
Novel Anti-LY6G6D/CD3 T-Cell–Dependent Bispecific Antibody for the Treatment of Colorectal Cancer
Wang P, Sun LL, Clark R, Hristopoulos M, Chiu CP, Dillon M, Lin W, Lo AA, Chalsani S, Das Thakur M, Zimmerman Savill KM, Rougé L, Lupardus P, Piskol R, Husain B, Ellerman D, Shivva V, Leong SR, Ovacik M, Totpal K, Wu Y, Spiess C, Lee G, Leipold DD, Polson AG |
Molecular cancer therapeutics | 2022 |
|
Bioassay Development for Bispecific Antibodies—Challenges and Opportunities
AC Register, SS Tarighat, HY Lee |
International journal of molecular sciences | 2021 |
|
Chimeric Antigen Receptor–Modified T Cells and T Cell–Engaging Bispecific Antibodies: Different Tools for the Same Job
M Schwerdtfeger, MR Benmebarek, S Endres, M Subklewe, V Desiderio, S Kobold |
Current Hematologic Malignancy Reports | 2021 |
|
Overcoming the challenges associated with CD3+ T-cell redirection in cancer
A Singh, S Dees, IS Grewal |
British Journal of Cancer | 2021 |
|
A scDb-based trivalent bispecific antibody for T-cell-mediated killing of HER3-expressing cancer cells
N Aschmoneit, S Steinlein, L Kühl, O Seifert, RE Kontermann |
Scientific Reports | 2021 |
|
Fc-comprising scDb-based trivalent, bispecific T-cell engagers for selective killing of HER3-expressing cancer cells independent of cytokine release
N Aschmoneit, L Kühl, O Seifert, RE Kontermann |
Journal for ImmunoTherapy of Cancer | 2021 |
|
Overcoming Challenges for CD3-Bispecific Antibody Therapy in Solid Tumors
J Middelburg, K Kemper, P Engelberts, AF Labrijn, J Schuurman, T van Hall |
Cancers | 2021 |
|
Bispecific Antibodies: A Smart Arsenal for Cancer Immunotherapies
G You, J Won, Y Lee, D Moon, Y Park, SH Lee, SW Lee |
Human vaccines | 2021 |
|
Dichotomous impact of affinity on the function of T cell engaging bispecific antibodies
M Poussin, A Sereno, X Wu, F Huang, J Manro, S Cao, C Carpenito, A Glasebrook, DJ Powell, SJ Demarest |
Journal for ImmunoTherapy of Cancer | 2021 |
|
Potent ex vivo armed T cells using recombinant bispecific antibodies for adoptive immunotherapy with reduced cytokine release
JA Park, BH Santich, H Xu, LG Lum, NK Cheung |
Journal for ImmunoTherapy of Cancer | 2021 |
|
Generation of T-cell-redirecting bispecific antibodies with differentiated profiles of cytokine release and biodistribution by CD3 affinity tuning
L Haber, K Olson, MP Kelly, A Crawford, DJ DiLillo, R Tavaré, E Ullman, S Mao, L Canova, O Sineshchekova, J Finney, A Pawashe, S Patel, R McKay, S Rizvi, E Damko, D Chiu, K Vazzana, P Ram, K Mohrs, A DOrvilliers, J Xiao, S Makonnen, C Hickey, C Arnold, J Giurleo, YP Chen, C Thwaites, D Dudgeon, K Bray, A Rafique, T Huang, F Delfino, A Hermann, JR Kirshner, MW Retter, R Babb, D MacDonald, G Chen, WC Olson, G Thurston, S Davis, JC Lin, E Smith |
Scientific Reports | 2021 |
|
One size does not fit all: navigating the multi-dimensional space to optimize T-cell engaging protein therapeutics
W Chen, F Yang, C Wang, J Narula, E Pascua, I Ni, S Ding, X Deng, ML Chu, A Pham, X Jiang, KC Lindquist, PJ Doonan, TV Blarcom, YA Yeung, J Chaparro-Riggers |
mAbs | 2021 |
|
Attenuating CD3 affinity in a PSMAxCD3 bispecific antibody enables killing of prostate tumor cells with reduced cytokine release
K Dang, G Castello, SC Clarke, Y Li, A Balasubramani, A Boudreau, L Davison, KE Harris, D Pham, P Sankaran, HS Ugamraj, R Deng, S Kwek, A Starzinski, S Iyer, W van Schooten, U Schellenberger, W Sun, ND Trinklein, R Buelow, B Buelow, L Fong, P Dalvi |
Journal for ImmunoTherapy of Cancer | 2021 |
|
Viro-antibody therapy: engineering oncolytic viruses for genetic delivery of diverse antibody-based biotherapeutics
RE Kontermann, G Ungerechts, DM Nettelbeck |
mAbs | 2021 |
|
A Novel Approach for Quantifying the Pharmacological Activity of T-Cell Engagers Utilizing In Vitro Time Course Experiments and Streamlined Data Analysis
A Vyver, M Eigenmann, M Ovacik, C Pohl, S Herter, T Weinzierl, T Fauti, C Klein, T Lehr, M Bacac, A Walz |
The AAPS Journal | 2021 |
|
Development of bispecific antibodies in China: overview and prospects
J Zhang, J Yi, P Zhou |
2020 | |
|
Affinity Maturation of B7-H6 Translates into Enhanced NK Cell–Mediated Tumor Cell Lysis and Improved Proinflammatory Cytokine Release of Bispecific Immunoligands via NKp30 Engagement
L Pekar, K Klausz, M Busch, B Valldorf, H Kolmar, D Wesch, HH Oberg, S Krohn, AS Boje, CL Gehlert, L Toleikis, S Krah, T Gupta, B Rabinovich, S Zielonka, M Peipp |
Journal of immunology (Baltimore, Md. : 1950) | 2020 |
